Brian Taylor Slingsby - 22 Sep 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Director
Issuer ticker: MLYS
Reported as of: 22 Sep 2026
Net transaction value: -$3,005,303
SEC form: 4
Accepted by SEC: 24 Sep 2026, 21:49:40 UTC
Prior SEC filing: 20 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

Brian Taylor Slingsby filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 24 Sep 2026.

Key facts

This page summarizes Brian Taylor Slingsby's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Sep 2026, 21:49.

Change

Previous filing in this sequence was filed on 20 Feb 2026.
Current net transaction value: -$3,005,303.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001963901 Primary reporting owner

Slingsby Brian Taylor

Relationship: Director
Address: 1700 WESTLAKE AVE. N, SUITE 200, THINKSPACE, SEATTLE
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 24 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Sale

Transaction value: $3,005,303
Shares: -104,320
Change %: -1.3%
Price: $28.81
Shares after: 7,805,718
Date: 22 Sep 2026
Ownership: See footnote
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares of common stock sold by Catalys Pacific Fund, LP. See footnote (3).

Footnote F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.700 to $28.905. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Represents shares of common stock held of record by Catalys Pacific Fund, LP. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP, and Mr. Slingsby is the managing partner of Catalys Pacific, LLC. Accordingly, Mr. Slingsby may be deemed to share voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Mr. Slingsby disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.